Adenosine

Generic Name: Adenosine

Brand Names: Adenocard, Viva-drops Lubricating Eye Drops

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₃N_₅O_₄

CAS Number: 58-61-7

Unique Ingredient Identifier: K72T3FS567

Background: The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by dipyridamole and [regadenson]. Adenosine is also indicated in the treatment of supraventricular tachycardia.

Adenosine was granted FDA approval on 30 October 1989.

Indication: Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy in patients unable to adequately exercise. It is also indicated to convert sinus rhythm of paroxysmal supraventricular tachycardia.

Associated Conditions: Paroxysmal Supraventricular Tachycardia (PSVT), Pulmonary Arterial Hypertension (PAH), SVT, Supraventricular Tachycardia (SVT)

Clinical Trials

Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions

Phase 4

Recruiting

Conditions: Premature Ventricular Contraction (PVC)

Interventions: Drug: Adenosine

First Posted Date: 2017-07-14

Last Posted Date: 2024-08-19

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 100

Registration Number: NCT03218137

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation

Phase 2

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Adenosine
Drug: Isoproterenol

First Posted Date: 2017-01-26

Last Posted Date: 2017-12-13

Lead Sponsor: University of Michigan

Target Recruit Count: 131

Registration Number: NCT03032965

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Adenosin to Rapidly Reverse Left Ventricle Impairment in Takotsubo Syndrome

Phase 2

Terminated

Conditions: Takotsubo Syndrome
Takotsubo Cardiomyopathy

Interventions: Drug: Adenosine
Drug: Saline solution

First Posted Date: 2016-08-16

Last Posted Date: 2018-10-23

Lead Sponsor: University Hospital of Ferrara

Target Recruit Count: 5

Registration Number: NCT02867878

Locations: 🇮🇹
University Hospital of Ferrara, Cona, Ferrara, Italy

Adenosine as an Adjunct to Blood Cardioplegia

Phase 2

Conditions: Pathological Processes
Cardiomyopathies

Interventions: Drug: Adenosine

First Posted Date: 2016-02-15

Last Posted Date: 2017-04-20

Lead Sponsor: Amphia Hospital

Target Recruit Count: 100

Registration Number: NCT02681913

Locations: 🇳🇱
Amphia Hospital, Breda, Noord-Brabant, Netherlands

Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging

Not Applicable

Withdrawn

Conditions: MRI Scans

Interventions: Drug: Adenosine
Drug: Regadenoson
Drug: O-15 labeled radioactive water
Device: MRI
Device: PET Imaging

First Posted Date: 2015-11-20

Last Posted Date: 2020-09-14

Lead Sponsor: University of Utah

Registration Number: NCT02608944

Locations: 🇺🇸
University of Utah, Radiology Research, Salt Lake City, Utah, United States

Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart

Phase 1

Completed

Conditions: Sinus Bradycardia
Atrioventricular Block

Interventions: Drug: Adenosine
Procedure: Cardiac catheterization

First Posted Date: 2015-06-04

Last Posted Date: 2018-02-08

Lead Sponsor: Columbia University

Target Recruit Count: 80

Registration Number: NCT02462941

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Differential Effect of High (200μg/kg/Min) Adenosine Dose on Fractional Flow Reserve in Patients Presenting Variation of FFR ≥0.05 During the Usual Dose of Adenosine Infusion (140μg/kg/Min).

Phase 3

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Adenosine infusion at 200μg/Kg/min

First Posted Date: 2015-01-29

Last Posted Date: 2017-01-10

Lead Sponsor: University of Patras

Target Recruit Count: 30

Registration Number: NCT02350439

Locations: 🇬🇷
Patras University Hospital, Patras, Greece

CONTRAST (Can cONTrast Injection Better Approximate FFR compAred to Pure reSTing Physiology?)

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Adenosine
Drug: Contrast Media
Drug: Resting conditions

First Posted Date: 2014-07-09

Last Posted Date: 2016-05-16

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 763

Registration Number: NCT02184117

Locations: 🇫🇷
Hôpital Louis Pradel, Lyon, France
🇧🇪
Cardiovascular Center (OLV-Ziekenhuis), Aalst, Belgium
🇳🇱
Catharina Hospital, Eindhoven, Noord-Brabant, Netherlands

and more 8 locations